Lv61
1998 积分 2024-06-06 加入
Antibody–peptide conjugates deliver covalent inhibitors blocking oncogenic cathepsins
3天前
已完结
Associations of general and central obesity with risk of premature mortality among Chinese adults: A nationwide prospective cohort study
10天前
已完结
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial
25天前
已完结
Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study
25天前
已完结
Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study
25天前
已完结
Pharmacokinetics and Pharmacodynamics of Bimagrumab (BYM338)
1个月前
已完结
Is Weight Loss–Induced Muscle Mass Loss Clinically Relevant?
1个月前
已完结
First muscle-growing antibody heads to the FDA, with obesity opportunities on the horizon
1个月前
已完结
Muscle matters: the effects of medically induced weight loss on skeletal muscle
1个月前
已完结
Balancing weight and muscle loss in GLP1 receptor agonist therapy
1个月前
已完结
皖公网安备34019202002308
